NASDAQ:SGEN

Seagen Stock Forecast, Price & News

$164.09
+5.90 (+3.73 %)
(As of 08/4/2021 03:15 PM ET)
Add
Compare
Today's Range
$158.60
$165.14
50-Day Range
$142.45
$161.10
52-Week Range
$133.20
$213.94
Volume65,190 shs
Average Volume835,520 shs
Market Capitalization$29.85 billion
P/E Ratio50.33
Dividend YieldN/A
Beta0.83
30 days | 90 days | 365 days | Advanced Chart
Receive SGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for Seagen and its competitors with MarketBeat's FREE daily newsletter.


Seagen logo

About Seagen

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company markets ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of metastatic urothelial cancers; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops Tisotumab Vedotin for metastatic cervical cancer and other solid tumors; ladiratuzumab vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and SpringWorks Therapeutics, Inc. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Social Links


MarketRank

Overall MarketRank

2.32 out of 5 stars

Medical Sector

233rd out of 1,309 stocks

Biological Products, Except Diagnostic Industry

32nd out of 179 stocks

Analyst Opinion: 2.3Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 4.2Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Seagen (NASDAQ:SGEN) Frequently Asked Questions

Is Seagen a buy right now?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Seagen in the last year. There are currently 6 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Seagen stock.
View analyst ratings for Seagen
or view top-rated stocks.

What stocks does MarketBeat like better than Seagen?

Wall Street analysts have given Seagen a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Seagen wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Seagen?

Seagen saw a decrease in short interest during the month of July. As of July 15th, there was short interest totaling 2,400,000 shares, a decrease of 19.5% from the June 30th total of 2,980,000 shares. Based on an average trading volume of 804,500 shares, the short-interest ratio is presently 3.0 days. Approximately 1.3% of the company's shares are short sold.
View Seagen's Short Interest
.

When is Seagen's next earnings date?

Seagen is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Seagen
.

How were Seagen's earnings last quarter?

Seagen Inc. (NASDAQ:SGEN) released its quarterly earnings data on Thursday, July, 29th. The biotechnology company reported ($0.47) earnings per share for the quarter, beating analysts' consensus estimates of ($0.61) by $0.14. Seagen had a net margin of 25.06% and a trailing twelve-month return on equity of 19.02%.
View Seagen's earnings history
.

How has Seagen's stock price been impacted by COVID-19?

Seagen's stock was trading at $104.51 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, SGEN shares have increased by 56.8% and is now trading at $163.83.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for SGEN?

15 equities research analysts have issued 12-month price targets for Seagen's stock. Their forecasts range from $145.00 to $254.00. On average, they expect Seagen's share price to reach $184.75 in the next year. This suggests a possible upside of 12.8% from the stock's current price.
View analysts' price targets for Seagen
or view top-rated stocks among Wall Street analysts.

Who are Seagen's key executives?

Seagen's management team includes the following people:
  • Dr. Clay B. Siegall, Co-Founder, Chairman, Pres & CEO (Age 60, Pay $2.64M)
  • Mr. Todd E. Simpson, Chief Financial Officer (Age 60, Pay $620.67k)
  • Ms. Jean I. Liu, Gen. Counsel, Exec. VP of Legal Affairs & Corp. Sec. (Age 53, Pay $963.45k)
  • Mr. Charles R. Romp, Exec. VP of Commercial U.S. (Age 53, Pay $829.16k)
  • Dr. Roger D. Dansey M.D., Chief Medical Officer (Age 64, Pay $1.65M)
  • Dr. Vaughn B. Himes, Chief Technical Officer (Age 60)
  • Peggy Pinkston, VP of Investor Relations
  • Ms. Nancy Whiting B.Sc., Pharm.D., Exec. VP of Corp. Strategy, Alliances & Communications
  • Ms. Natasha A. Hernday, Exec. VP of Corp. Devel. (Age 49)
  • Mr. Matt Skelton, VP of Marketing

What is Clay B. Siegall's approval rating as Seagen's CEO?

107 employees have rated Seagen CEO Clay B. Siegall on Glassdoor.com. Clay B. Siegall has an approval rating of 99% among Seagen's employees. This puts Clay B. Siegall in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Seagen's key competitors?

What other stocks do shareholders of Seagen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Seagen investors own include NVIDIA (NVDA), AbbVie (ABBV), Advanced Micro Devices (AMD), Gilead Sciences (GILD), salesforce.com (CRM), QUALCOMM (QCOM), Tesla (TSLA), Micron Technology (MU), Netflix (NFLX) and Alibaba Group (BABA).

What is Seagen's stock symbol?

Seagen trades on the NASDAQ under the ticker symbol "SGEN."

Who are Seagen's major shareholders?

Seagen's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Manning & Napier Group LLC (0.51%), Sumitomo Mitsui Trust Holdings Inc. (0.24%), Pinnacle Associates Ltd. (0.18%), New York State Common Retirement Fund (0.08%), Victory Capital Management Inc. (0.08%) and Alliancebernstein L.P. (0.04%). Company insiders that own Seagen stock include Bros Advisors Lp Baker, Charles R Romp, Clay B Siegall, Clay B Siegall, Daniel G Welch, David W Gryska, Jean I Liu, Lip Bu Tan, Marc E Lippman, Morgan E Obrien, Roger D Dansey, Srinivas Akkaraju, Todd E Simpson and Vaughn B Himes.
View institutional ownership trends for Seagen
.

Which institutional investors are selling Seagen stock?

SGEN stock was sold by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, Handelsbanken Fonder AB, Oregon Public Employees Retirement Fund, Alliancebernstein L.P., Advisor Group Holdings Inc., Sumitomo Mitsui Trust Holdings Inc., Pinnacle Associates Ltd., and Oppenheimer & Co. Inc.. Company insiders that have sold Seagen company stock in the last year include Charles R Romp, Clay B Siegall, Daniel G Welch, David W Gryska, Jean I Liu, Morgan E Obrien, Roger D Dansey, Todd E Simpson, and Vaughn B Himes.
View insider buying and selling activity for Seagen
or view top insider-selling stocks.

Which institutional investors are buying Seagen stock?

SGEN stock was acquired by a variety of institutional investors in the last quarter, including Manning & Napier Group LLC, EFG Asset Management Americas Corp., IFM Investors Pty Ltd, New York State Common Retirement Fund, Arizona State Retirement System, Advisors Asset Management Inc., Victory Capital Management Inc., and Tuttle Tactical Management.
View insider buying and selling activity for Seagen
or or view top insider-buying stocks.

How do I buy shares of Seagen?

Shares of SGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Seagen's stock price today?

One share of SGEN stock can currently be purchased for approximately $163.83.

How much money does Seagen make?

Seagen has a market capitalization of $29.81 billion and generates $2.18 billion in revenue each year. The biotechnology company earns $613.67 million in net income (profit) each year or $3.30 on an earnings per share basis.

How many employees does Seagen have?

Seagen employs 2,092 workers across the globe.

Does Seagen have any subsidiaries?

The following companies are subsidiares of Seagen: Cascadian Therapeutics.

When was Seagen founded?

Seagen was founded in 1998.

What is Seagen's official website?

The official website for Seagen is www.seattlegenetics.com.

Where are Seagen's headquarters?

Seagen is headquartered at 21823 30TH DRIVE SE SUITE, BOTHELL WA, 98021.

How can I contact Seagen?

Seagen's mailing address is 21823 30TH DRIVE SE SUITE, BOTHELL WA, 98021. The biotechnology company can be reached via phone at 425-527-4000 or via email at [email protected]


This page was last updated on 8/4/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.